KDR and neoplasm: This drug has been shown to inhibit tumor cell proliferation by blocking the Ras/Raf/MAPK pathway and angiogenesis by blocking both VEGFR and PDGFR signaling, thus slowing the growth of new blood vessels within the tumor [11].